[en] The development of new vaccines, containing protective antigens that are more and more well characterized, is hindered by the lack of adjuvants able both to amplify immune response and to control it qualitatively. A number of tumors and infectious diseases could be treated with adjuvant preparations that would adequately intensify and modulate specific immune response; in particular, the possibility to specifically induce a Th1 response seems to be of paramount importance for the prevention and for the cure of these diseases. Furthermore, these adjuvants must be as safe as possible, not only for commercial applications, but also in the respect of laboratory animals' welfare. This review describes the different adjuvants presently used in vaccinology, classifying them following their chemical nature and presenting for each category the knowledge concerning their activity and toxicity.
Disciplines :
Veterinary medicine & animal health
Author, co-author :
Vermout, Sandy
Denis, M.
Losson, Bertrand ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires > Parasitologie et pathologie des maladies parasitaires
Mignon, Bernard ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires > Parasitologie et pathologie des maladies parasitaires
AHLERS J.D., BELYAKOV I.M., BERZOFSKY J.A. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med., 2003, 3, 285-301.
AUDIBERT F.M., LISE L.D. Adjuvants: current status, clinical perspectives and future prospects. Trends Pharmacol. Sci., 1993, 14, 174-178.
BARR T.A., McCORMICK A.L., CARLRING J., HEATH A.W. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology, 2003, 109, 87-92.
BILLIAU A., MATTHYS P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol., 2001, 70, 849-860.
BUATES S., MATLASHEWSKI G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis., 1999, 179, 1485-1494.
CARLRING J., BARR T.A., BUCKLE A.M., HEATH A.W. Anti-CD28 has a potent adjuvant effect on the antibody response to soluble antigens mediated through CTLA-4 by-pass. Eur. J. immunol., 2003, 33, 135-142.
CARSON D.A., RAZ E. Oligonucleotide Adjuvants for T helper 1 (Th1)-specific Vaccination. J. Exp. Med., 1997, 186, 1621-1622.
CARSON W.E., YU H., DIERKSHEIDE J., PFEFFER K., BOUCHARD P., CLARK R., DURBIN J., BALDWIN A.S., PESCHON J., JOHNSON P.R., KU G., BAUMANN H., CALIGIURI M.A. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol., 1999, 162, 4943-4951.
CEDARLANE LABORATORIES LIMITED. The adjuvant guide. [enligne] (2003). Adresse URL: http://www.cedarlanelabs.com/catalogues.asp?company=AdjuvantGuide Consulté le 27/01/03.
CHU R.S., TARGONI O.S., KRIEG A.M., LEHMANN P.V., HARDING C.V. CpG oligonucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med., 1997, 186, 1623-1631.
CITTERIO S., RESCIGNO M., FOTI M., GRANUCCI F., AGGUJARO D., GASPERI C., MATYSZAK M.K., GIROLOMONI G., RICCIARDI-CASTAGNOLI P. Dendritic cells as natural adjuvants. Methods, 1999, 19, 142-147.
COMOY E., CAPRON A., THYPHRONITIS G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int. Immunol., 1997, 9, 523-531.
CONSEIL CANADIEN DE PROTECTION DES ANIMAUX. Lignes directrices: production d'anticorps. [en ligne] (2002). Adresse URL: http:// www.ccac.ca/french/gdlines/antibody/antibodyfr.pdf Consulté le 27/01/03.
COX J.C., COULTER A.R. Adjuvants: a classification and review of their mode of action. Vaccine, 1997, 15, 248-256.
DALPKE A., ZIMMERMANN S., HEEG K. Immunopharmacology of CpG DNA. Biol. Chem., 2002, 383, 1491-1500.
DOCKRELL D.H., KINGHORN G.R. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother., 2001, 48, 751-755.
GRISWOLD R. CHUA guidelines concerning use of polyclonal antibody generation/production. State University of New York. [en ligne] (2002). Adresse URL: http:// www.upstate.edu/dlar/hsconly/Policies/guide_antibody.htm Consulté le 27/01/03.
GRUN J.L., MAURER P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell. Immunol., 1989, 121, 134-145.
HALPERIN S.A., VAN NEST G., SMITH B., ABTAHI S., WHILEY H., EIDEN J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine, 2003, 21, 2461-2467.
HALPERN M.D., KURLANDER M.J., PISETSKY D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell. Immunol., 1996, 67, 72-78.
HILGERS L.A.T., SNIPPE H. DDA as an immunological adjuvant. Res. Immunol., 1992, 143, 494-501.
HOGENESCH H. Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine, 2002, 20: Suppl 3, S34-9.
HORZINEK M.C., SCHIJNS V.E.C.J., DENIS M., DESMETTRE P., BABIUK L.A. Adjuvants and vehicles. In: Pastoret P.P., Blancou J., Vannier P., Verschueren C. (Eds.), Veterinary Vaccinology. Elsevier: Amsterdam, 1997, 140-148.
HUNTER R.L. Overview of vaccine adjuvants: present and future. Vaccine, 2002, 20: Suppl 3, S7-12.
JÄGER E., RINGHOFFER M., DIENES H.P., ARAND M., KARBACH J., JÄER D., ILSEMANN C., HAGEDORN M., OESCH F., KNUTH A. Granulocyte- Macrophage-Colony-Stimulating Factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer., 1996, 67, 54-62.
KANDIMALLA E.R., YU D., AGRAWAL S. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther., 2002, 4, 122-129.
MOINGEON P., HAENSLER J., LINDBERG A. Towards the rational design of Th1 adjuvants. Vaccine, 2001, 19, 4363-4372.
MURRAY R., COHEN P., HARDEGREE M.C. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy, 1972, 30, 146-151.
MUTWIRI G., PONTAROLLO R., BABIUK S., GRIEBEL P., VAN DRUNEN LITTEL-VAN DEN HURK S., MENA A., TSANG C. ALCON V., NICHANI A., IOANNOU X., GOMIS S., TOWNSEND H., HECKER R., POTTER A., BABIUK L.A. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet. Immunol. Immunopathol., 2003, 91, 89-103.
NICKLAS W. Aluminium salts. Res. Immunol., 1992, 143, 489-494.
O'HAGAN D.T. Recent developments in vaccine delivery. Curr. Drug Targets Infect. Disord., 2001, 1, 273-286.
PERSING D.H., COLER R.N., LACY M.J., JOHNSON D.A., BALDRIDGE J.R., HERSHBERG R.M., REED S.G. Taking toll:lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol., 2002, 10 suppl, S32-S37.
RELYVELD E.H. Preparation and use of calcium phosphate adsorbed vaccines. Dev. Biol. Stand., 1986, 65, 131-136.
RIZZA P., FERRANTINI M., CAPONE I., BELARDELLI F. Cytokines as natural adjuvants for vaccines: where are we now? Trends Immunol., 2002, 23, 381-383.
SCHIJNS V.E. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol., 2001, 21, 75-85.
SEEBER S.J., WHITE J.L., HEM S.L. Predicting the absorption of proteins by aluminium-containing adjuvants. Vaccine, 1991, 9, 201-203.
SJOLANDER A., COX J.C. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv. Drug Deliv. Rev., 1998, 34, 321-338.
STANLEY M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol., 2002, 27, 571-577.
VAN DER LUBBEN I.M., VERHOEF J.C., BORCHARD G., JUNGINGER H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev., 2001, 52, 139-144.
WEERATNA R.D., McCLUSKIE M.J., XU Y., DAVIS H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine, 2000, 18, 1755-1762.
ZIMMERMAN S., HEEG K., DALPKE A. Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3′ sequence modifications. Vaccine, 2003, 21, 990-995.
